"GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","ReportingType_Code","ReportingType_Desc","Nature_Code","Nature_Desc","Units_Code","Units_Desc","GeoArea_Code","GeoArea_Desc","Year","TimeDetail","Value","ValueType","Source","Footnotes","ISO3CD","X","Y"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2004.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2005.0,"","9","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2006.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2007.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2008.0,"","23","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2009.0,"","24","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2010.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2011.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2012.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2013.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2014.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2015.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","4","Afghanistan",2016.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AFG","66.02688198","33.83160199"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2000.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2001.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2002.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2003.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2004.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2005.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2006.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2007.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2008.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2009.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2010.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2011.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2012.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2013.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2014.0,"","19","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2015.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","2","Africa",2016.0,"","32","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2001.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2003.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","8","Albania",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ALB","20.06660928","41.13897007"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2000.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2001.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2004.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2005.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2013.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","12","Algeria",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DZA","2.678164227","28.15940032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2000.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2001.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2002.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2003.0,"","40","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2004.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2005.0,"","40","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2006.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2007.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2008.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2009.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2010.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2011.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2012.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2013.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2014.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2015.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","19","Americas",2016.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2007.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2008.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2009.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2010.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2011.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2012.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2013.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","20","Andorra",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AND","1.576257417","42.54548611"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","24","Angola",2015.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AGO","17.57817062","-12.33724746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","24","Angola",2016.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AGO","17.57817062","-12.33724746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2005.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2006.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2007.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2008.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2010.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2011.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2013.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2014.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","28","Antigua and Barbuda",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ATG","-61.7999755","17.07761471"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2000.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2001.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2002.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2003.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2004.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2005.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2006.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2007.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2008.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2012.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2013.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","32","Argentina",2016.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARG","-65.14563274","-35.19446255"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2000.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2002.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2003.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2004.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2006.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2014.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","51","Armenia",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARM","44.93839317","40.29499741"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2000.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2001.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2002.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2003.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2004.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2005.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2006.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2007.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2008.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2009.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2010.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2011.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2012.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2013.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2014.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","142","Asia",2016.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2004.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2005.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2006.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2007.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2009.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2010.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2011.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2012.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2015.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","36","Australia",2016.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUS","134.3499412","-25.57717202"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2004.0,"","69.69354","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2005.0,"","69.66722","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2006.0,"","71.15714","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2007.0,"","72.67618","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2008.0,"","65.20184","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2009.0,"","66.85303","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2010.0,"","71.91167","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2011.0,"","89.3009","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2012.0,"","89.95501","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2013.0,"","90.95966","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2014.0,"","91.79603","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2015.0,"","91.98088","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","53","Australia and New Zealand",2016.0,"","93.16295","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2000.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2001.0,"","34","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2002.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2003.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2004.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2005.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2006.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2007.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2008.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2009.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2010.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2011.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2012.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2013.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2014.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","40","Austria",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AUT","14.14172472","47.58704857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2001.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2002.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2003.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2004.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2005.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2006.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2007.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2008.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2009.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2010.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2011.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","31","Azerbaijan",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","AZE","50.01064725","40.39229544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2005.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2006.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2007.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2009.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2010.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2011.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2012.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2013.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2014.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2015.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","44","Bahamas",2016.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHS","-78.05111663","24.69546597"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2000.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","48","Bahrain",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BHR","50.5490754","26.04407747"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","50","Bangladesh",2012.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGD","89.17660788","22.86961622"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","50","Bangladesh",2013.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGD","89.17660788","22.86961622"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","50","Bangladesh",2014.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGD","89.17660788","22.86961622"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","50","Bangladesh",2015.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGD","89.17660788","22.86961622"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","50","Bangladesh",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGD","89.17660788","22.86961622"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2001.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2002.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2003.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2010.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2013.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2014.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","52","Barbados",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRB","-59.5346489","13.13648273"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2000.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2001.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2006.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","112","Belarus",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLR","28.04940161","53.54193075"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2006.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2007.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2008.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2009.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2010.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2011.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2012.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2013.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2014.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2015.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","56","Belgium",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BEL","4.660976456","50.64104975"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2005.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2006.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2007.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2008.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2012.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","84","Belize",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BLZ","-88.70199554","17.19965901"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2008.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2009.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2010.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2013.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","64","Bhutan",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BTN","90.45098484","27.39598568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2000.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2001.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2003.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2004.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2005.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2008.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2009.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2011.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2013.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","70","Bosnia and Herzegovina",2016.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BIH","17.78584332","44.16845548"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","72","Botswana",2013.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BWA","23.81380223","-22.18810073"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","72","Botswana",2014.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BWA","23.81380223","-22.18810073"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","72","Botswana",2015.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BWA","23.81380223","-22.18810073"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","72","Botswana",2016.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BWA","23.81380223","-22.18810073"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2000.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2002.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2003.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2004.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2005.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2006.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2007.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2008.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2009.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2010.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2011.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2012.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2013.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2015.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","76","Brazil",2016.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRA","-53.08432878","-10.77668561"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2000.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2008.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2010.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2011.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","96","Brunei Darussalam",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BRN","114.6288563","4.49736984"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2000.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2001.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2002.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2003.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2004.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2007.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2010.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","100","Bulgaria",2016.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BGR","25.23763153","42.75731323"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","854","Burkina Faso",2014.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BFA","-1.742843829","12.27491081"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","854","Burkina Faso",2015.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BFA","-1.742843829","12.27491081"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","854","Burkina Faso",2016.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BFA","-1.742843829","12.27491081"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","108","Burundi",2013.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BDI","29.89080992","-3.366387428"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","108","Burundi",2014.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BDI","29.89080992","-3.366387428"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","108","Burundi",2015.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BDI","29.89080992","-3.366387428"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","108","Burundi",2016.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","BDI","29.89080992","-3.366387428"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2013.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2014.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","132","Cabo Verde",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CPV","-23.63544151","15.07791834"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","116","Cambodia",2012.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KHM","104.922836","12.71163737"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","116","Cambodia",2013.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KHM","104.922836","12.71163737"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","116","Cambodia",2014.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KHM","104.922836","12.71163737"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","116","Cambodia",2015.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KHM","104.922836","12.71163737"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","116","Cambodia",2016.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KHM","104.922836","12.71163737"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","124","Canada",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CAN","-101.6575058","57.72360191"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","124","Canada",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CAN","-101.6575058","57.72360191"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","124","Canada",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CAN","-101.6575058","57.72360191"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","124","Canada",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CAN","-101.6575058","57.72360191"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","124","Canada",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CAN","-101.6575058","57.72360191"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2000.0,"","1","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2001.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2002.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2003.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2004.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2005.0,"","23","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2006.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2007.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2008.0,"","30","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2009.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2010.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2011.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2012.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2013.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2014.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2015.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","29","Caribbean",2016.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2000.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2001.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2003.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2004.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2005.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2006.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2007.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2008.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2009.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2010.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","135","Caucasus and Central Asia",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2000.0,"","70.10713","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2001.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2002.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2003.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2004.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2005.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2006.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2007.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2008.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2009.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2010.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2011.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2012.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2013.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2014.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","13","Central America",2016.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2000.0,"","91.78499","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2001.0,"","93.20575","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2002.0,"","95.80018","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2003.0,"","96.78936","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2004.0,"","98.02469","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2005.0,"","88.49198","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2006.0,"","81.18998","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2007.0,"","71.26636","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2008.0,"","63.09406","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2009.0,"","56.37397","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2010.0,"","77.97569","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2011.0,"","98.46241","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2012.0,"","98.15005","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2013.0,"","97.77869","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2014.0,"","98.67245","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2015.0,"","97.7399","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","143","Central Asia",2016.0,"","98.61274","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2006.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2008.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2009.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2010.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2011.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2012.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2013.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2014.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","152","Chile",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHL","-71.23029019","-35.2652885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2005.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","156","China",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHN","104.1403375","32.30955217"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2000.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2001.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2003.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2004.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2005.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2006.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2008.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2009.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2010.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2011.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2012.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2013.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2014.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","170","Colombia",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COL","-73.07446751","3.888209046"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2000.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2001.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2002.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2003.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2004.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2009.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2012.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","184","Cook Islands",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","COK","-159.7711391","-21.22696458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2008.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2009.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2010.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2011.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2015.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","188","Costa Rica",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CRI","-84.19712782","9.970998683"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2014.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","191","Croatia",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HRV","17.95874553","45.45172212"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2005.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","192","Cuba",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CUB","-79.54460144","22.10030366"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2008.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2009.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2010.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2011.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2012.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2014.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","196","Cyprus",2016.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CYP","33.22285964","35.05659437"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","203","Czechia",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CZE","15.33151382","49.73913871"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","408","Democratic People's Republic of Korea",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRK","127.1803633","40.1462645"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2001.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2002.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2003.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2004.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2005.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2006.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2007.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2008.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2009.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2010.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2011.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2012.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2014.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2015.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","208","Denmark",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DNK","9.326571283","56.03829721"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2000.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2001.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2002.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2003.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2004.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2005.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2006.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2007.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2008.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2009.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2010.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2011.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2012.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2013.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2014.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2015.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)",2016.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2000.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2001.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2002.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2003.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2004.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2005.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2006.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2007.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2009.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2010.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2011.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2012.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2013.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2014.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2015.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","515","Developing regions",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","262","Djibouti",2012.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DJI","42.18274707","11.56004161"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","262","Djibouti",2013.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DJI","42.18274707","11.56004161"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","262","Djibouti",2014.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DJI","42.18274707","11.56004161"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","262","Djibouti",2015.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DJI","42.18274707","11.56004161"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","262","Djibouti",2016.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DJI","42.18274707","11.56004161"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2001.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2013.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","212","Dominica",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DMA","-61.3493756","15.43391378"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2005.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2006.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2007.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2008.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2009.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2010.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2011.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2012.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2013.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2014.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2015.0,"","19","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","14","Eastern Africa",2016.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2000.0,"","1.72766","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2001.0,"","2.74229","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2002.0,"","3.52099","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2003.0,"","3.5589","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2004.0,"","3.47581","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2005.0,"","77.31445","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2006.0,"","86.40845","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2007.0,"","84.9124","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2008.0,"","94.10626","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2009.0,"","97.65551","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2010.0,"","98.84364","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2011.0,"","98.55484","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2012.0,"","98.53231","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2013.0,"","98.5482","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2014.0,"","98.63542","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2015.0,"","98.56869","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","30","Eastern Asia",2016.0,"","98.55772","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2000.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2001.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2002.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2003.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2004.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2005.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","518","Eastern Asia (excluding Japan)",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2000.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2001.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2002.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2010.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2013.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","151","Eastern Europe",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2011.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2012.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2013.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2014.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2015.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","218","Ecuador",2016.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ECU","-78.37005241","-1.447785891"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2000.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2013.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","818","Egypt",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EGY","29.77468534","26.57438204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2003.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2004.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2005.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2006.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2007.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2008.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2009.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2010.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2011.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2013.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2014.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2015.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","222","El Salvador",2016.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLV","-88.86862995","13.73603564"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","232","Eritrea",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ERI","38.11074289","16.12894644"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","232","Eritrea",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ERI","38.11074289","16.12894644"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2000.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2001.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2002.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","233","Estonia",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","EST","25.84093481","58.68487172"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2011.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2012.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2013.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","748","Eswatini",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWZ","31.50149288","-26.56471011"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2000.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2001.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2002.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2003.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2004.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2005.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2006.0,"","72.11386","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2007.0,"","73.2733","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2008.0,"","73.2733","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2009.0,"","71.94241","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2010.0,"","78.51691","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2011.0,"","79.26246","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2012.0,"","80.05062","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2013.0,"","85.57322","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2014.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","150","Europe",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2005.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2007.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2012.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","242","Fiji",2016.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FJI","177.9660884","-17.83301566"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","246","Finland",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FIN","23.308447","61.91586738"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2010.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2011.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2012.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2013.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2014.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2015.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","250","France",2016.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FRA","2.457288129","46.62660861"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","270","Gambia",2012.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GMB","-15.39944785","13.45295927"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","270","Gambia",2013.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GMB","-15.39944785","13.45295927"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","270","Gambia",2014.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GMB","-15.39944785","13.45295927"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","270","Gambia",2015.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GMB","-15.39944785","13.45295927"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","270","Gambia",2016.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GMB","-15.39944785","13.45295927"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2001.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2002.0,"","40","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2003.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2004.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2005.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2006.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2008.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2009.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2010.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2011.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2012.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2013.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2014.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2015.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","268","Georgia",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GEO","43.3713615","42.04813028"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2002.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2003.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2004.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2005.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2006.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2008.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2010.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2011.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2012.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2013.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2015.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","276","Germany",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","DEU","10.3806066","51.08862743"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","288","Ghana",2012.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GHA","-1.205623522","7.964825185"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","288","Ghana",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GHA","-1.205623522","7.964825185"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","288","Ghana",2014.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GHA","-1.205623522","7.964825185"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","288","Ghana",2015.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GHA","-1.205623522","7.964825185"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","288","Ghana",2016.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GHA","-1.205623522","7.964825185"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2007.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2008.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2009.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2010.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2011.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2012.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2013.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2014.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2015.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","300","Greece",2016.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRC","22.58307827","39.47301873"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2002.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2003.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2004.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2005.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2006.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2007.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2008.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2009.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2010.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2011.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2012.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2013.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","308","Grenada",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GRD","-61.68248568","12.11238395"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","320","Guatemala",2016.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GTM","-91.2312746","15.00273719"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2001.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2002.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2003.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2004.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2005.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2006.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2007.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2008.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2009.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2010.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2011.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2014.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","328","Guyana",2016.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GUY","-58.97322037","4.788012784"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","332","Haiti",2016.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HTI","-72.33640958","18.40426539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2010.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","348","Hungary",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","HUN","19.41221519","47.1651448"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2003.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2004.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2005.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2010.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2011.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","352","Iceland",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISL","-19.02116966","64.79134763"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2011.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2012.0,"","36","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2013.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2014.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2015.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","356","India",2016.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IND","79.3608464","22.34642074"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2003.0,"","21","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2004.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2005.0,"","23","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2006.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2007.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2008.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2009.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2010.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2011.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2012.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2013.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2014.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2015.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","360","Indonesia",2016.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IDN","113.9174","-0.994582204"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2001.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","364","Iran (Islamic Republic of)",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRN","54.19766348","32.74370885"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2001.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2002.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2003.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2004.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2005.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2006.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2007.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2008.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2009.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2010.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2011.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2012.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2013.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2014.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2015.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","368","Iraq",2016.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","IRQ","43.76606267","33.05013795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2001.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2007.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2008.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2010.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2011.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2012.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","376","Israel",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ISR","34.62277992","31.06164552"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","380","Italy",2013.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ITA","12.57022427","42.79917282"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","380","Italy",2014.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ITA","12.57022427","42.79917282"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","380","Italy",2015.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ITA","12.57022427","42.79917282"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","380","Italy",2016.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ITA","12.57022427","42.79917282"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2003.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2005.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2006.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2007.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2009.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2010.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2011.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2012.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2013.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2014.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2015.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","388","Jamaica",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JAM","-77.31068409","18.15616857"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2008.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2011.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2013.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2015.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","392","Japan",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JPN","139.2716103","36.6554539"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2000.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2001.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2003.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2006.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2008.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2009.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","400","Jordan",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","JOR","37.13024774","30.65365973"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","398","Kazakhstan",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KAZ","66.65359159","48.01963494"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","404","Kenya",2015.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KEN","37.86096816","0.534797278"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","404","Kenya",2016.0,"","32","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KEN","37.86096816","0.534797278"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2009.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2010.0,"","21","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2011.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2012.0,"","9","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2013.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2014.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2015.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","296","Kiribati",2016.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KIR","-157.5643005","1.768837732"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2005.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2007.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2008.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2014.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","414","Kuwait",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KWT","47.49305029","29.53949468"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2000.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2012.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2014.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","417","Kyrgyzstan",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KGZ","74.52324839","41.46204516"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2000.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2001.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2002.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2003.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2004.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2005.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2006.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2007.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2008.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2009.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2010.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2011.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2012.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2013.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2014.0,"","20","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2015.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","432","Landlocked developing countries (LLDCs)",2016.0,"","34","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2000.0,"","60.06961","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2001.0,"","61.06421","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2002.0,"","56.81798","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2003.0,"","55.55228","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2004.0,"","56.96647","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2005.0,"","55.79256","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2006.0,"","54.55838","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2007.0,"","52.20517","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2008.0,"","55.5606","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2009.0,"","59.75887","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2010.0,"","60.65385","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2011.0,"","67.52138","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2012.0,"","66.1557","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2013.0,"","61.19683","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2014.0,"","73.11566","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2015.0,"","71.75119","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","419","Latin America and the Caribbean",2016.0,"","73.47605","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2000.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2010.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2011.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","428","Latvia",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LVA","26.42461876","56.64196636"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2005.0,"","1","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2006.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2007.0,"","1","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2008.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2009.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2010.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2011.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2012.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2013.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2014.0,"","22","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2015.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","199","Least Developed Countries (LDCs)",2016.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2000.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2001.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2002.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2003.0,"","14","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2004.0,"","24","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2005.0,"","34","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2006.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2007.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2008.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2009.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2010.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2011.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2012.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2013.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2014.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","422","Lebanon",2016.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBN","35.89391711","33.92152458"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2001.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2002.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2003.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2004.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2005.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2006.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2007.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2009.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2010.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2011.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2012.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2013.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2014.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2015.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","426","Lesotho",2016.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LSO","28.25362195","-29.58041814"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2001.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2002.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2003.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","434","Libya",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LBY","18.0295985","27.04042819"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2000.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2002.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2003.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2004.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2012.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","440","Lithuania",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LTU","23.90517807","55.33680309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","442","Luxembourg",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LUX","6.092656563","49.77679538"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","442","Luxembourg",2014.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LUX","6.092656563","49.77679538"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","442","Luxembourg",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LUX","6.092656563","49.77679538"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","442","Luxembourg",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LUX","6.092656563","49.77679538"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","454","Malawi",2015.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MWI","33.4884625","-13.40819859"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","454","Malawi",2016.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MWI","33.4884625","-13.40819859"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2005.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2006.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","458","Malaysia",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MYS","116.8346314","5.452415309"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2007.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2008.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2010.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2014.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","462","Maldives",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDV","73.09672546","-0.614385021"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2003.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2004.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2005.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2006.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2007.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2008.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2009.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2010.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2011.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2012.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2015.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","470","Malta",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MLT","14.44617519","35.89194275"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2000.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2001.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2002.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2003.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2004.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2005.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2006.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2007.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2008.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2009.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2010.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2011.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2012.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2013.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2014.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2015.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","584","Marshall Islands",2016.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MHL","171.0839119","7.110213497"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2004.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2005.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2006.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2007.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2008.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2009.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2010.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2011.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2013.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2014.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","480","Mauritius",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MUS","57.568022","-20.28581998"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2005.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2006.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2007.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2008.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2009.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2010.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2011.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2012.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2013.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2014.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2015.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","54","Melanesia",2016.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2002.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2006.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2007.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2013.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","484","Mexico",2016.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MEX","-102.5148166","23.93378032"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2000.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2001.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2002.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2003.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2004.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2005.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2006.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2007.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2008.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2009.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2010.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2011.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2012.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2013.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2014.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","57","Micronesia",2016.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2000.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2001.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2002.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2003.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2004.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2005.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2006.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2007.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2008.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2009.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2010.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2011.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2012.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2013.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2014.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2015.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","583","Micronesia (Federated States of)",2016.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","FSM","158.225216","6.880670092"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2005.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2006.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2007.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2008.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2009.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2010.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2011.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2012.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2013.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2014.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2015.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","17","Middle Africa",2016.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2000.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2012.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","496","Mongolia",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNG","103.0728057","46.83892054"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","499","Montenegro",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MNE","19.25214024","42.78717043"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2004.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2006.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2014.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","504","Morocco",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MAR","-6.281942841","31.8440131"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","508","Mozambique",2016.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MOZ","38.18479941","-14.27963886"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2008.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2009.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2010.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2011.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2013.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2014.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2015.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","104","Myanmar",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MMR","96.51752295","21.19332882"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2001.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2002.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2003.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2004.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2005.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2009.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2012.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","520","Nauru",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NRU","166.92313","-0.528742623"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","524","Nepal",2016.0,"","25","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NPL","83.94678863","28.25866332"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2005.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2006.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2007.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2008.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2010.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2011.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2012.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","528","Netherlands",2016.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NLD","5.331480568","51.86728884"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2011.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2012.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2014.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","554","New Zealand",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NZL","170.4755673","-43.98721568"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","562","Niger",2014.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NER","9.400167877","17.42143036"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","562","Niger",2015.0,"","16","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NER","9.400167877","17.42143036"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","562","Niger",2016.0,"","37","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NER","9.400167877","17.42143036"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2003.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2005.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2012.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","570","Niue",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NIU","-169.8601693","-19.05000475"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2000.0,"","52.45078","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2001.0,"","54.41089","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2002.0,"","56.34756","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2003.0,"","56.59766","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2004.0,"","68.02373","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2005.0,"","68.17647","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2006.0,"","68.47933","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2007.0,"","68.06207","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2008.0,"","55.38707","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2009.0,"","55.64696","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2010.0,"","56.00045","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2011.0,"","60.35722","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2012.0,"","64.18877","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2013.0,"","74.25883","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2014.0,"","81.86496","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2015.0,"","88.77256","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","15","Northern Africa",2016.0,"","90.7316","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2000.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2002.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2003.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","746","Northern Africa (exc. Sudan)",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2005.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2006.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2007.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2008.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2009.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2010.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2011.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2012.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2013.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2014.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2015.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","21","Northern America",2016.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2000.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2001.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2002.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2003.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2004.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2005.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2006.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2007.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2008.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2009.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2010.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2011.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2012.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2013.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2014.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2015.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","154","Northern Europe",2016.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2000.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2001.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2003.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2004.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2005.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2006.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2010.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2011.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2012.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2013.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2014.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2015.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","578","Norway",2016.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","NOR","11.47846389","61.34311134"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2001.0,"","1","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2002.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2003.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2004.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2005.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2006.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2007.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2008.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2009.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2010.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2011.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2012.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2013.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2014.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2015.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","9","Oceania",2016.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","512","Oman",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","OMN","57.87743482","21.98805614"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2009.0,"","30","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2010.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2011.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2012.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2013.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2014.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2015.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","586","Pakistan",2016.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAK","68.80479684","29.36491634"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2000.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2001.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2002.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2003.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2007.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2008.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2009.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2010.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2011.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2012.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2014.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2015.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","585","Palau",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PLW","134.5733878","7.502307591"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2000.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2001.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2002.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2003.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2004.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2005.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2006.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2007.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2008.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2009.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2010.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2011.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2012.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2013.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","591","Panama",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PAN","-81.26616623","8.450965746"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2005.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2006.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2007.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2008.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2009.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2010.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2011.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2012.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2013.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2014.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2015.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","600","Paraguay",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRY","-60.54854225","-21.70216237"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2007.0,"","9","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2008.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2009.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2010.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2011.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2012.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2014.0,"","44","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2015.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","604","Peru",2016.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PER","-71.82093277","-13.58939705"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2009.0,"","19","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2010.0,"","10","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2011.0,"","36","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2012.0,"","42","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2014.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2015.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","608","Philippines",2016.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PHL","120.8601418","14.16591706"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2000.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2005.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2013.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","616","Poland",2016.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","POL","19.40660158","52.1226733"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2000.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2001.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2002.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2003.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2004.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2005.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2006.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2007.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2008.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2009.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2010.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2011.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2012.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2013.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2014.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2015.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","61","Polynesia",2016.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2000.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2001.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2002.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2003.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2004.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2005.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2006.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2013.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","620","Portugal",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PRT","-7.961599811","39.68509315"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2002.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2003.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2006.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2007.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2015.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","634","Qatar",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","QAT","51.19152467","25.28355379"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2000.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2001.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2002.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2003.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","410","Republic of Korea",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KOR","127.8610254","36.45201023"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2002.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2015.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","498","Republic of Moldova",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MDA","28.4650624","47.20236795"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2000.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2001.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2010.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2014.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2015.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","642","Romania",2016.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ROU","24.98481009","45.83893563"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2000.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2001.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2014.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2015.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","643","Russian Federation",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RUS","99.01404926","61.61899849"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","646","Rwanda",2015.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RWA","29.92310194","-1.999842114"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","646","Rwanda",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","RWA","29.92310194","-1.999842114"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2015.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","659","Saint Kitts and Nevis",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","KNA","-62.76628613","17.33994219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2000.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2001.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2002.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2003.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2004.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2005.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2006.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2007.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2008.0,"","22","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2009.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2010.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2011.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2012.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2013.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2014.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","662","Saint Lucia",2016.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LCA","-60.96529553","13.89405601"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2003.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2004.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2005.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2006.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2007.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2009.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2010.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2012.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2013.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","670","Saint Vincent and the Grenadines",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VCT","-61.19024321","13.24627968"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2002.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2003.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2004.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2005.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2006.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2007.0,"","36","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2008.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2009.0,"","14","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2010.0,"","30","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2011.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2012.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2013.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2014.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2015.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","882","Samoa",2016.0,"","44","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","WSM","-172.4430749","-13.61541469"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2005.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2007.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2008.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2009.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2010.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2011.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2012.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2013.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2014.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2015.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","674","San Marino",2016.0,"","36","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SMR","12.46329038","43.93841766"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","678","Sao Tome and Principe",2014.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","STP","6.609772265","0.241554875"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","678","Sao Tome and Principe",2015.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","STP","6.609772265","0.241554875"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","678","Sao Tome and Principe",2016.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","STP","6.609772265","0.241554875"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2006.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2011.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2012.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","682","Saudi Arabia",2016.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SAU","44.54763347","24.12594211"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","686","Senegal",2014.0,"","13","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SEN","-14.46636926","14.35920905"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","686","Senegal",2015.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SEN","-14.46636926","14.35920905"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","686","Senegal",2016.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SEN","-14.46636926","14.35920905"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2000.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2001.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2002.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2006.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2009.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2011.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2013.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2014.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","688","Serbia",2016.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SRB","20.805876","44.03145697"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2007.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2013.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","690","Seychelles",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYC","55.46561591","-4.678053059"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","694","Sierra Leone",2015.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLE","-11.78306584","8.568604164"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","694","Sierra Leone",2016.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SLE","-11.78306584","8.568604164"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2001.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2002.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2003.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2004.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2008.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2013.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2014.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2015.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","702","Singapore",2016.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SGP","103.8107883","1.361009155"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2002.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","703","Slovakia",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVK","19.48495604","48.70741446"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2008.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2009.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2010.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2015.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","705","Slovenia",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SVN","14.82209486","46.11958061"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2000.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2001.0,"","14","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2002.0,"","14","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2003.0,"","14","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2004.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2005.0,"","23","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2006.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2007.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2008.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2009.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2010.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2011.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2012.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2013.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2014.0,"","27","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2015.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","722","Small island developing States (SIDS)",2016.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2000.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2001.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2002.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2003.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2004.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2005.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2006.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2007.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2008.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2009.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2010.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2011.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2012.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2013.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2014.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2015.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","710","South Africa",2016.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZAF","24.67184355","-29.99957544"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2000.0,"","61.1002","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2001.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2002.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2003.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2004.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2005.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2006.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2007.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2008.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2009.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2010.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2011.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2012.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2013.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2014.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2015.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","5","South America",2016.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2000.0,"","9.68686","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2001.0,"","8.42011","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2002.0,"","8.55614","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2003.0,"","16.87892","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2004.0,"","20.21892","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2005.0,"","22.02036","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2006.0,"","32.61537","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2007.0,"","44.44848","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2008.0,"","56.29388","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2009.0,"","61.07212","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2010.0,"","63.40099","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2011.0,"","69.2225","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2012.0,"","64.7325","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2013.0,"","73.62507","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2014.0,"","56.15277","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2015.0,"","58.45271","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","35","South-Eastern Asia",2016.0,"","69.68646","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2000.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2001.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2002.0,"","44","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2003.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2004.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2005.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2006.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2007.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2008.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2009.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2010.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2011.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2012.0,"","55","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2013.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2014.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2015.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","18","Southern Africa",2016.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2000.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2001.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2002.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2003.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2004.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2005.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2006.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2007.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2008.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2009.0,"","9","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2010.0,"","11","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2011.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2012.0,"","40","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2014.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2015.0,"","67","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","34","Southern Asia",2016.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2000.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2001.0,"","24","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2002.0,"","25","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2003.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2004.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2005.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2006.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2007.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2008.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2009.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2010.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2011.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2012.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","39","Southern Europe",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2004.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2009.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2010.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2012.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2013.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","724","Spain",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ESP","-3.554078296","40.39211472"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2001.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2002.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2003.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2007.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","144","Sri Lanka",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","LKA","80.70489654","7.614693343"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2000.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2001.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2003.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2004.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2005.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2006.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2007.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","275","State of Palestine",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","PSE","35.25694122","31.94347933"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2000.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2001.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2002.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2003.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2004.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2005.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2006.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2007.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2008.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2009.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2010.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2011.0,"","3","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2012.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2013.0,"","5","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2014.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2015.0,"","16","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","202","Sub-Saharan Africa",2016.0,"","22","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2000.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2001.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2002.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2003.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2004.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2005.0,"","62","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2006.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2007.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2008.0,"","70","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2009.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2010.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2011.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2012.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2013.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2014.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2015.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","738","Sub-Saharan Africa (inc. Sudan)",2016.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","729","Sudan",2012.0,"","24","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","729","Sudan",2013.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","729","Sudan",2014.0,"","61","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","729","Sudan",2015.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","729","Sudan",2016.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","740","Suriname",2013.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SUR","-55.90626394","4.132603197"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","740","Suriname",2014.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SUR","-55.90626394","4.132603197"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","740","Suriname",2015.0,"","28","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SUR","-55.90626394","4.132603197"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","740","Suriname",2016.0,"","44","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SUR","-55.90626394","4.132603197"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2000.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2001.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2002.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2003.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2006.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2008.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2009.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2012.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2013.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","752","Sweden",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SWE","14.3775338","60.60103109"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2005.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2006.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2007.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2008.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2009.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2010.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2011.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2012.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2014.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2015.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","756","Switzerland",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","CHE","8.223158","46.96617097"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2000.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2001.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2002.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2003.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2004.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2005.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2006.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2007.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2008.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2009.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2010.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2011.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2012.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2013.0,"","51","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2014.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2015.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","760","Syrian Arab Republic",2016.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","SYR","38.50466565","35.01676176"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2000.0,"","59","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2001.0,"","72","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2002.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2003.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2004.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2005.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2007.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2008.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2010.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2012.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2014.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2015.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","762","Tajikistan",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TJK","69.294998","38.43069666"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2001.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2002.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2003.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2006.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2007.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2008.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2009.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2011.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2012.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2013.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2015.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","764","Thailand",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","THA","101.0202951","15.13089239"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2000.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2001.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2002.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2004.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2005.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2006.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2007.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2011.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2013.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2014.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2015.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","807","The former Yugoslav Republic of Macedonia",2016.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","MKD","21.7007909","41.60048068"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","626","Timor-Leste",2016.0,"","22","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TLS","125.9451052","-8.797497247"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2003.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2004.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2005.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2006.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2007.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2008.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2009.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2010.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2011.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2012.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2014.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2015.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","776","Tonga",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TON","-175.1959991","-21.19511329"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2001.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2002.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2003.0,"","73","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2004.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2005.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2006.0,"","78","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2007.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2008.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2009.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2010.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2011.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2012.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2015.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","780","Trinidad and Tobago",2016.0,"","65","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TTO","-61.29389504","10.41877263"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2005.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2009.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2011.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2014.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2015.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","788","Tunisia",2016.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUN","9.572737411","34.11439971"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2001.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2002.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2003.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2006.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2007.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2008.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2009.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2010.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2011.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2012.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2014.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","792","Turkey",2016.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUR","35.42890329","38.9899684"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2000.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2001.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2002.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2003.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2004.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2005.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2006.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2007.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2008.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2009.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2010.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","795","Turkmenistan",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TKM","58.9787665","40.0912346"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2001.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2003.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2004.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2005.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2006.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2007.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2008.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2009.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2010.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2011.0,"","90","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2012.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2013.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2014.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","798","Tuvalu",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TUV","178.6679611","-7.460048071"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2000.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2002.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2003.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2004.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2005.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2006.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2007.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2008.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2009.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2010.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2011.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2012.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2014.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2015.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","804","Ukraine",2016.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UKR","31.40270802","49.00735945"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2000.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2001.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2002.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2003.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2004.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2005.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2006.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2007.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2008.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2009.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2010.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2011.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2012.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2013.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","784","United Arab Emirates",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ARE","53.98279159","23.43322219"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2000.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2001.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2002.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2003.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2004.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2005.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2006.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2007.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2008.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2009.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2010.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2011.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2012.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2013.0,"","88","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2014.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2015.0,"","91","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","826","United Kingdom of Great Britain and Northern Ireland",2016.0,"","89","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","GBR","-2.23830539","53.27691757"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","834","United Republic of Tanzania",2014.0,"","29","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TZA","34.80521182","-6.265332606"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","834","United Republic of Tanzania",2015.0,"","57","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TZA","34.80521182","-6.265332606"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","834","United Republic of Tanzania",2016.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","TZA","34.80521182","-6.265332606"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","858","Uruguay",2013.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","URY","-56.01387025","-32.8002838"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","858","Uruguay",2014.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","URY","-56.01387025","-32.8002838"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","858","Uruguay",2015.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","URY","-56.01387025","-32.8002838"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","858","Uruguay",2016.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","URY","-56.01387025","-32.8002838"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2000.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2001.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2002.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2003.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2004.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2005.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2006.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2007.0,"","44","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2008.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2009.0,"","8","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2010.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2011.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2012.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2013.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2014.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2015.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","860","Uzbekistan",2016.0,"","99","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","UZB","63.11944558","41.77560518"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2009.0,"","6","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2010.0,"","31","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2011.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2012.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2013.0,"","38","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2014.0,"","50","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2015.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","862","Venezuela (Bolivarian Republic of)",2016.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VEN","-66.15642084","7.121324748"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2007.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2008.0,"","97","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2009.0,"","96","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2010.0,"","98","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2011.0,"","93","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2012.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2013.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2014.0,"","94","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2015.0,"","92","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","704","Viet Nam",2016.0,"","95","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","VNM","105.802499","10.09643079"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2000.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2001.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2002.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2003.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2004.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2005.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2006.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2007.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2008.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2009.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2010.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2011.0,"","0","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2012.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2013.0,"","4","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2014.0,"","7","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2015.0,"","12","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","11","Western Africa",2016.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2000.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2001.0,"","68","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2002.0,"","66","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2003.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2004.0,"","69","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2005.0,"","75.39853","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2006.0,"","71","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2007.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2008.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2009.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2010.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2011.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2012.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2013.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2014.0,"","75","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2015.0,"","74","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","145","Western Asia",2016.0,"","76","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2000.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2001.0,"","85","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2002.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2003.0,"","77","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2004.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2005.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2006.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2007.0,"","84","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2008.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2009.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2010.0,"","87","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2011.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2012.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2013.0,"","82","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2014.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2015.0,"","79","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)",2016.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2000.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2001.0,"","2","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2002.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2003.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2004.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2005.0,"","48","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2006.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2007.0,"","52","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2008.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2009.0,"","53","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2010.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2011.0,"","80","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2012.0,"","83","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2013.0,"","81","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2014.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2015.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","155","Western Europe",2016.0,"","86","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2000.0,"","15","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2001.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2002.0,"","17","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2003.0,"","18","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2004.0,"","20","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2005.0,"","30","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2006.0,"","32","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2007.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2008.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2009.0,"","38","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2010.0,"","39","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2011.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2012.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2013.0,"","54","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2014.0,"","56","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2015.0,"","60","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","1","World",2016.0,"","64","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","",""
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2005.0,"","21","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2006.0,"","26","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2007.0,"","32","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2008.0,"","35","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2009.0,"","38","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2010.0,"","43","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2011.0,"","46","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2012.0,"","40","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2013.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2014.0,"","45","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2015.0,"","41","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","887","Yemen",2016.0,"","49","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","YEM","45.22389143","15.22242099"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","894","Zambia",2014.0,"","33","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZMB","27.850329","-14.59701056"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","894","Zambia",2015.0,"","47","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZMB","27.850329","-14.59701056"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","894","Zambia",2016.0,"","58","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZMB","27.850329","-14.59701056"
"3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","G","Global","E","Estimated data","PERCENT","Percentage","716","Zimbabwe",2016.0,"","63","Float","WHO/UNICEF coverage estimates 2016 revision, July 2017","","ZWE","29.86909584","-19.00075492"
